Finch Therapeutics

Finch Therapeutics is a biotechnology company developing novel microbiome drugs to serve patients with serious unmet medical needs.

Finch Therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform.

Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.

Finch uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients.

Finch’s Human-First Discovery® platform enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. Finch’s platform uniquely enables development of both complete microbiome communities and rationally selected consortia to restore microbiome functionality and resolve conditions driven by dysbiosis, or disruption of the microbiome.

 

Finch’s lead program, CP101, is an investigational microbiome drug with Fast Track and Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile infection. The company is also developing FIN-211 for the treatment of children with autism spectrum disorder and CP101 for the treatment of chronic hepatitis B.

 

Finch Therapeutics has a strategic partnership with Takeda Pharmaceuticals focused on the development of microbiome drugs for inflammatory bowel diseases.

 

Finch is backed by Avenir Growth Capital, OCV Partners, Shumway Capital, SIG, SymBiosis, TPTF, Baupost Group, Humboldt Fund, MSD Capital and others. The company raised $90M in Series D round on Sep 17, 2020. This brings Finch's total funding to $188.8M to date.

 

 

  • Year founded: 2017
  • Funding Info: $188.8M over 5 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Somerville
  • State: Massachusetts
  • Country: United States
Related businesses